Drugs / 500 mg/m2, Q3W, intravenous injection (IV)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03838848 Background | May 2019 → Jul 2022 | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 500 mg/m2, Q3W, intravenous injection (IV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03838848 ↗ |
| Route | Intravenous | “intravenous injection (IV)” NCT03838848 ↗ |